Vesugen

Most Common Uses

Vesugen is primarily investigated for its role in supporting cardiovascular health and combating age-related vascular decline. One of its primary purported uses is the normalization of blood vessel function. The peptide is also often associated with improving blood circulation and flow, a benefit that is consistently mentioned across various sources, indicating a key area of interest in its application. It’s also thought to support the health and strength of endothelial cells, which line the blood vessels and are essential for proper vascular function.

Vascular-Related Conditions

Furthermore, Vesugen is suggested to be potentially beneficial for a range of conditions related to vascular health. These include atherosclerosis, a condition characterized by the buildup of plaque in the arteries; coronary heart disease, involving the narrowing or blockage of the heart’s arteries; hypertension, or high blood pressure; hypertonia, another term for high blood pressure; encephalopathy, a general term for brain disease, damage, or malfunction; vegetative-vascular dystonia, a condition involving the autonomic nervous system; hypercholesterolemia, characterized by high levels of cholesterol in the blood; and varicose veins, which are enlarged and twisted veins.

Blood Flow, Oxygenation, and Vascular Repair

Beyond these specific conditions, Vesugen has been described as having the potential to enhance blood flow, repair leaky blood vessels, decrease edema (swelling caused by excess fluid), reduce hypoxia (lack of oxygen), and even support the blood-brain barrier, which protects the brain from harmful substances. Research has also investigated its use in the treatment of lower limbs chronic arterial insufficiency in older adults, indicating a specific area of clinical study. Additionally, Vesugen has been explored for its effectiveness in treating vasculogenic erectile dysfunction, which can be a manifestation of atherosclerosis, highlighting another targeted clinical application.

Anti-Aging and Geroprotective Effects

Another significant area of interest in Vesugen research is its potential role in anti-aging and geroprotection. Studies have suggested that it may slow the rate of aging based on biological age indicators, which are measurable markers that reflect an individual’s physiological age. Its geroprotective effect has been particularly noted in patients with organic brain syndrome, suggesting a potential benefit for this specific population in mitigating age-related decline.

Cellular and Metabolic Support

Research further suggests that Vesugen may influence cellular processes associated with both cellular aging and metabolism, indicating a broader impact beyond just vascular function. This influence may extend to potentially impacting lipid and glucose metabolism, suggesting a role in maintaining metabolic health. Additionally, Vesugen has been speculated to contribute to the maintenance of the extracellular matrix (ECM), the structural framework of tissues, which is important for tissue regeneration and repair. Its potential to support the recovery of vascular tissues following injury or degeneration also points to a role in regenerative processes.

Cardiac and Cognitive Function

Moreover, it has been associated with decreasing cardiac arrhythmia and angina attacks in individuals with coronary heart disease, as well as normalizing blood pressure in patients with hypertension. In specific populations, such as individuals working in harmful conditions, Vesugen has been suggested to improve memory, attention, thinking, perceptual motor reactions, and mental capacity, potentially reducing the degree of aging.

Therapeutic Potential

The multitude of these purported uses, particularly those related to improving blood flow and vascular health, suggests that this is a primary area of focus for Vesugen’s application. The connection to aging may arise from the well-established link between age-related decline in vascular function and overall health. It is plausible that compromised blood circulation, whether due to aging or disease, leads to peptide deficiencies and impaired protein synthesis in blood vessels, creating an environment where Vesugen could potentially play a role in normalizing function and restoring these essential processes.

Warnings and Cautions

While Vesugen has shown a good safety profile in studies, there is limited information on its long-term use in humans. Some individuals may experience mild side effects such as allergic reactions or gastrointestinal discomfort, though these are uncommon.

One study observed prooxidant activity, which is the opposite of an antioxidant effect, suggesting a potential negative impact on oxidative stress. The same study also noted an inhibition of hemopoiesis, the production of blood cells, indicated by a decrease in certain hematopoietic stem cells.

Vesugen, particularly in supplement form, is often intended to be used in addition to conventional medical treatments and should not be considered a replacement for them. This recommendation underscores its role as a supplementary therapy rather than a primary treatment for serious medical conditions.

Dosages

The recommended dosages for Vesugen vary depending on the formulation. For the capsule form, the typical recommendation for adults is 1 to 2 capsules (10 to 20 mg) taken once or twice a day, preferably during food intake. The duration of this supplementation is often suggested to be between 10 to 30 days, with a recommendation to repeat the procedure after a period of 4 to 6 months.

For the lingual form of Vesugen, which is administered as drops under the tongue, the recommended dosage for adults is typically 5 to 6 drops (0.25 to 0.35 ml) held under the tongue for 10 to 15 minutes before eating, 3 to 4 times a day. The duration of intake for the lingual form is generally around 1 month, with a recommendation to repeat the intake in 3 to 6 months.

Mechanism of Action:

Research suggests that Vesugen exerts its biological effects through several mechanisms, with a primary focus on regulating gene expression and protein synthesis. Studies indicate that short peptides like Vesugen can penetrate into the nuclei and nucleoli of cells, where they interact with DNA and histone proteins. This interaction allows them to influence which genes are activated or repressed, thereby modulating the production of specific proteins. One key epigenetic mechanism through which Vesugen may act is the regulation of DNA methylation, a process that can alter gene expression without changing the underlying DNA sequence.

The vasoprotective properties of Vesugen are thought to be linked to this epigenetic regulation, specifically affecting genes that encode proteins involved in the antioxidant system and maintaining endothelial functional activity. By influencing the expression of these genes, Vesugen may help protect blood vessels from damage and support their proper function. Research also indicates that Vesugen can normalize the endothelial synthesis of various proteins that are important for normal vascular function.

Furthermore, Vesugen has been shown to stimulate the synthesis of Ki-67, a protein associated with cell proliferation. Ki-67 is a marker of cell division and is often upregulated in tissues undergoing repair or regeneration. Molecular docking studies have revealed that Vesugen interacts with the promoter region of the MKI67 gene, which encodes the Ki-67 protein, providing a direct mechanism for this increased synthesis

Vascular Effects

Vesugen is often linked to improved blood flow, which plays a role in many of its reported benefits. It may also help repair leaky blood vessels, which can ease swelling and support overall tissue health. Strengthening vascular function in this way may also reduce issues like edema and low oxygen levels in tissue. Some sources suggest Vesugen helps maintain the blood-brain barrier, which acts as a protective filter for the brain.

Research has shown that Vesugen promotes nitric oxide (NO)-dependent relaxation and prostaglandin I2 (PGI2)-IP-mediated vasorelaxation, both processes that help widen blood vessels and support better circulation. It’s also been observed to influence the production of several proteins in the endothelium, such as SIRT1, endothelin-1, connexin, Ki67, Cx43, VEGF, and p53. These proteins are tied to vascular health, aging, and conditions like atherosclerosis and restenosis.

Cellular Effects

At the cellular level, Vesugen has been found to stimulate the proliferation of both immune and stem cells, suggesting a role in tissue repair and immune system modulation. In T helper cells, which are part of the immune system, it increases the expression of Ki-67, a marker linked to cell growth. In studies focused on accelerated aging, Vesugen helped restore cell structure and boosted their ability to multiply. There’s also evidence it can protect lab-grown neurons from aging-related changes and promote dendritogenesis, or the growth of neuron branches, hinting at possible neuroprotective effects.

It may influence how vascular cells behave by activating pathways tied to repair and maintenance, and it’s thought to affect nitric oxide (NO) production, important for healthy blood vessel function. Vesugen might also encourage cellular renewal by impacting how stem cells grow and specialize, helping support tissue-specific healing. Some findings suggest it could help preserve mitochondrial health and play a part in regulating metabolism at the cellular level. Overall, it appears to affect cell behavior through changes in gene activity, protein production, and how cells communicate within vascular and connective tissues.

Structure and Pharmacology

Vesugen is a tripeptide composed of three amino acids: Lysine, Glutamic acid, and Aspartic acid, arranged in the sequence Lys-Glu-Asp. Its molecular formula is C15H26N4O8, and it has a molecular weight of 390.39 g/mol. The International Union of Pure and Applied Chemistry (IUPAC) name for Vesugen is (2S)-2-amino]butanoyl]amino]butanedioic acid.

Pharmacologically, Vesugen exhibits biological activity against both cardiovascular and immune tissues. A key aspect of its pharmacology is its vasoprotective properties, which have been demonstrated in several studies. While Vesugen does not possess direct antioxidant activity, it has been shown to restrict lipid peroxidation of human lipoproteins by modifying their structure, suggesting an indirect role in mitigating oxidative stress, a major factor in atherosclerosis. The peptide also increases the stability of red blood cell membranes against osmotic hemolysis, indicating a protective effect on these cells.

Vesugen stimulates the proliferation of immune and stem cells, pointing to potential applications in immunomodulation and tissue regeneration. It also tissue-specifically stimulates the expression of differentiation factors, indicating a targeted action on certain cell types. Vesugen can regulate the status of DNA methylation, highlighting its epigenetic mechanism of action. It interacts with specific molecular targets within the body, suggesting a precise mechanism of action rather than a general effect

The pharmacological profile of Vesugen is characterized by its targeted effects on vascular and immune tissues, its ability to influence cellular processes through the regulation of gene expression, and its apparent tolerability in initial studies. The specific amino acid sequence of Lys-Glu-Asp dictates its chemical properties and its ability to interact with various biological molecules, ultimately leading to the observed pharmacological effects.

History

The development of Vesugen as a bioregulator for blood vessels is rooted in research focused on correcting pathological changes in the vascular system associated with various diseases. It was synthesized at the St. Petersburg Institute of Bioregulation and Gerontology, a prominent research institution known for its work on peptide bioregulators. The history of Vesugen is closely intertwined with the extensive research conducted by Professor Vladimir Khavinson, who discovered and studied numerous peptide bioregulators, including Vesugen.

Vesugen’s development took place in the 1980s and 1990s as part of a broader effort to create peptide-based pharmaceuticals. During this period, six medicinal peptide preparations, some developed under Professor Khavinson’s supervision, were approved for medical use in the USSR, Russia, and the Commonwealth of Independent States (CIS) countries. These preparations were primarily intended for use by the military medical service. Vesugen is classified as one of the short peptides synthesized from amino acids (di-, tri-, tetrapeptides) that emerged following the initial research and development of more complex polypeptide extracts. This shift towards shorter, more defined peptides allowed for a more targeted approach to understanding and utilizing their biological activities.

Clinical Trials

Vesugen for Anti-Aging

A 2015 study evaluated the geroprophylactic effects of the synthetic tripeptide Vesugen in 32 patients (18 men, 14 women) aged 41–83 years with chronic polymorbidity and organic brain syndrome in remission. The research focused on cellular and metabolic mechanisms underlying Vesugen’s anti-aging properties. Vesugen exhibited a significant anabolic effect, enhancing the function of the central nervous system and other vital organs, thereby decelerating aging as measured by biological age indicators.

Compared to Pinealon, Vesugen demonstrated a more pronounced geroprophylactic effect. However, it displayed prooxidant activity, as evidenced by chemiluminescence analysis. The peptide also reduced CD34+ hematopoietic polypotent cells in blood, indicating substantial inhibition of hemopoiesis and suggesting limited involvement of these cells in adaptive responses. Vesugen did not alter chromatin condensation, confirming its safety at the nuclear genetic level. [1]

The 2020 study investigates the geroprotective effects of the short peptides AEDG and KED on human mesenchymal stem cells (hMSCs) derived from oral tissues, specifically human periodontal ligament stem cells (hPLSCs) and human gingival mesenchymal stem cells (hGMSCs).

In the study, hMSCs at the 25th passage were divided into three groups: a control group (no peptide), a group treated with AEDG peptide, and a group treated with KED peptide. The effects of these peptides were assessed through immunofluorescence and RT-PCR, focusing on the expression of senescence markers p16 and p21. Results demonstrated that AEDG peptide reduced p16 and p21 mRNA expression by 1.56–2.44 times compared to the control group, while KED peptide reduced expression by 1.82–3.23 times.

The study concludes that AEDG and KED peptides exhibit geroprotective properties by delaying the expression of senescence markers, thereby preserving the morphology and function of oral hMSCs during long-term cultivation. These peptides are proposed as valuable supplementary substances in culture media to support large-scale in vitro expansion for stem cell therapy applications. The results align with prior evidence of the geroprotective effects of AEDG and KED peptides in animal and cellular models. [2]

Vesugen and Vasculogenic ED

The 2014 study evaluates the efficacy of the vasoactive tripeptide Vesugen in treating vasculogenic erectile dysfunction (ED) as a manifestation of lower limb chronic arterial insufficiency due to atherosclerosis in elderly patients. Atherosclerosis, identified as the primary cause of arterial obliterative diseases in 80–90% of cases, leads to endothelial dysfunction, contributing to conditions such as hypertension, diabetes, congestive heart failure, and impaired erectile function.

The research involved 41 patients with vasculogenic ED, focusing on the therapeutic impact of Vesugen monotherapy. Clinical and instrumental assessments, including blood flow measurements in the main penile arteries, were conducted before and after treatment. The results demonstrated significant improvements in penile arterial blood flow, as evidenced by both clinical outcomes and objective instrumental parameters following Vesugen administration. According to the study, Vesugen is an effective peptide bioregulator for improving vascular function in patients with atherosclerosis-related ED. [3]

Vesugen for Vascular Function

A study conducted in 2017 investigated the therapeutic potential of the vasoactive peptide Vesugen as a monotherapy for patients with chronic lower limb arterial insufficiency following surgical intervention. Atherosclerosis, responsible for 80–90% of lower limb chronic occlusive arterial disease cases, disrupts vascular wall self-regulation, and the study posits that supplementation with endogenous peptides like Vesugen can correct this dysfunction.

The research involved 41 patients who had undergone surgery for chronic lower limb ischemia. The efficacy of Vesugen monotherapy was evaluated through a comparative analysis of clinical outcomes and ultrasonic blood flow parameters in the lower limbs, measured before and after treatment.

The findings revealed significant improvements in lower limb blood flow, as demonstrated by both clinical assessments and ultrasonic indicators following Vesugen administration. The study concluded that Vesugen monotherapy is effective in enhancing vascular function in patients with chronic lower limb arterial insufficiency, supporting its role as a vasoactive peptide in improving blood flow and aiding post-surgical recovery in elderly and senile patients with atherosclerosis-related ischemia. [4]